NYSE - Nasdaq Real Time Price USD

Agilent Technologies, Inc. (A)

105.74

-1.28

(-1.20%)

As of 12:50:33 PM EDT. Market Open.

Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

SANTA CLARA, Calif., April 24, 2025--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including:

Business Wire yesterday

A
-1.20%
With 90% institutional ownership, Agilent Technologies, Inc. (NYSE:A) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in Agilent Technologies implies that they have significant influence...

Simply Wall St. 5 days ago

A
-1.20%
Reflecting On Research Tools & Consumables Stocks’ Q4 Earnings: Agilent (NYSE:A)

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers.

StockStory 7 days ago

A
-1.20%
TECH

AVTR
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif., April 17, 2025--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced st

Business Wire 8 days ago

A
-1.20%
Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif., April 16, 2025--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day.

Business Wire 8 days ago

A
-1.20%
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks 14 days ago

A
-1.20%
CNC
Heidi Kunz Resigns From Agilent Technologies (NYSE:A) Board as Share Price Falls 3%

Last week, Agilent Technologies (NYSE:A) experienced a price decline of 3%, a movement that may have been influenced by recent changes within the company's board. The announcement of Heidi Kunz's impending resignation from the board and its committees could have introduced some uncertainty, potentially impacting investor sentiment. Additionally, the broad market impact from President Trump's announcement of new tariffs, which saw significant declines in major indices like the Dow Jones and...

Simply Wall St. 21 days ago

A
-1.20%
Are Investors Undervaluing Agilent Technologies, Inc. (NYSE:A) By 24%?

Key Insights The projected fair value for Agilent Technologies is US$154 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 24 days ago

A
-1.20%
Agilent Technologies (A): A Top Pick For The Best Retirement Portfolio

We recently published the Best Retirement Portfolio for a 65-Year-Old. In this article, we are going to take a look at where Agilent Technologies, Inc. (NYSE:A) stands against other stocks in the best retirement portfolio. The American retirement system is feeling the strain, with challenges like shrinking fees, underfunded plans, and an aging population slowing […]

Insider Monkey 27 days ago

A
-1.20%
Agilent (A) Down 6.4% Since Last Earnings Report: Can It Rebound?

Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

A
-1.20%
Is Agilent Technologies (A) One of the Best Diagnostics Stocks to Invest in Right Now?

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take a look at where Agilent Technologies, Inc. (NYSE:A) stands against the other best diagnostics stocks to invest in right now. Overview of the Clinical Diagnostics Market According to a report by […]

Insider Monkey last month

A
-1.20%
Agilent Technologies (A) Unveils Digital Pathology Tools at US & Canadian Conference

We recently compiled a list of the Top 8 Trending AI Stock Updates On Wall Street Today. In this article, we are going to take a look at where Agilent Technologies Inc. (NYSE:A) stands against the other AI stocks. As the global AI race heats up with rapid developments in Asia, led by China, the […]

Insider Monkey last month

A
-1.20%
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif., March 24, 2025--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and

Business Wire last month

A
-1.20%
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

SANTA CLARA, Calif., March 20, 2025--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph.

Business Wire last month

A
-1.20%
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

SANTA CLARA, Calif., March 19, 2025--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy.

Business Wire last month

A
-1.20%
Should You Invest in the First Trust Water ETF (FIW)?

Sector ETF report for FIW

Zacks last month

A
-1.20%
WAT
-1.39%
Q4 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks

Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Sotera Health Company (NASDAQ:SHC) and its peers.

StockStory last month

SHC

AVTR

TECH
Research Tools & Consumables Stocks Q4 Recap: Benchmarking Bruker (NASDAQ:BRKR)

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bruker (NASDAQ:BRKR) and its peers.

StockStory last month

BRKR

TECH

AVTR
Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma

Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma. While this significant advancement in oncology diagnostics highlights the company's innovative edge, Agilent's stock saw a weekly decline of 3.51%. This price movement occurred against a backdrop of broader market volatility, driven by economic and political uncertainties including the Trump...

Simply Wall St. last month

A
-1.20%
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

SANTA CLARA, Calif., March 10, 2025--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive

Business Wire last month

A
-1.20%

Performance Overview

Return	A	S&P 500 (^GSPC)
YTD	-21.12%	-6.47%
1-Year	-21.88%	+8.97%
3-Year	-11.06%	+28.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agilent Technologies, Inc. (A)

Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

With 90% institutional ownership, Agilent Technologies, Inc. (NYSE:A) is a favorite amongst the big guns

Reflecting On Research Tools & Consumables Stocks’ Q4 Earnings: Agilent (NYSE:A)

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Heidi Kunz Resigns From Agilent Technologies (NYSE:A) Board as Share Price Falls 3%

Are Investors Undervaluing Agilent Technologies, Inc. (NYSE:A) By 24%?

Agilent Technologies (A): A Top Pick For The Best Retirement Portfolio

Agilent (A) Down 6.4% Since Last Earnings Report: Can It Rebound?

Is Agilent Technologies (A) One of the Best Diagnostics Stocks to Invest in Right Now?

Agilent Technologies (A) Unveils Digital Pathology Tools at US & Canadian Conference

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

Should You Invest in the First Trust Water ETF (FIW)?

Q4 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks

Research Tools & Consumables Stocks Q4 Recap: Benchmarking Bruker (NASDAQ:BRKR)

Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

Performance Overview